+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Anorexiant Drug Market by Product (Branded, Generic), Mechanism Of Action (Glp-1 Agonists, Lipase Inhibitors, Serotonin Agonists), Distribution Channel, Dosage Form, End User, Indication, Patient Age Group - Global Forecast 2025-2030- Product Image
Oral Anorexiant Drug Market by Product (Branded, Generic), Mechanism Of Action (Glp-1 Agonists, Lipase Inhibitors, Serotonin Agonists), Distribution Channel, Dosage Form, End User, Indication, Patient Age Group - Global Forecast 2025-2030- Product Image
New

Oral Anorexiant Drug Market by Product (Branded, Generic), Mechanism Of Action (Glp-1 Agonists, Lipase Inhibitors, Serotonin Agonists), Distribution Channel, Dosage Form, End User, Indication, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6148200
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Stage for Next-Generation Oral Anorexiant Therapies Amidst Escalating Obesity Challenges and Evolving Patient Expectations

The oral anorexiant landscape is being reshaped by a confluence of clinical breakthroughs, shifting patient demographics, and mounting regulatory scrutiny. As obesity rates escalate globally, the demand for effective, safe, and convenient weight-management solutions has reached an inflection point. In response, pharmaceutical innovators are channeling significant resources into the development of next-generation oral therapies capable of delivering sustained efficacy with an improved tolerability profile. This confluence of factors has elevated oral anorexiants from niche interventions to front-line therapeutic contenders.


Moreover, the advent of novel mechanisms of action, including glucagon-like peptide-1 modulators, lipase inhibitors, and serotonin receptor agonists, has broadened the therapeutic toolkit available to prescribers. These modalities offer differentiated approaches to appetite regulation and metabolic control, creating opportunities for tailored treatment regimens across diverse patient populations. Ultimately, this report offers a structured exploration of the current environment, analyzing the clinical, regulatory, and commercial levers that are defining the trajectory of oral anorexiant therapies.

Uncovering the Paradigm-Shifting Therapeutic Innovations and Emerging Healthcare Dynamics Redefining Oral Anorexiant Treatment Ecosystems

Over the past several years, the oral anorexiant market has experienced transformative shifts driven by technological innovation, evolving payer frameworks, and intensified patient engagement. Pharmaceutical developers have leveraged advancements in formulation science to extend the duration of action for GLP-1 agonists, while simultaneously optimizing oral bioavailability. Consequently, improved dosing regimens have emerged that balance sustained weight reduction with enhanced adherence potential.


Furthermore, digital health platforms have begun to integrate with therapeutic programs, offering real-time monitoring and patient support mechanisms. This convergence of pharmacotherapy and technology not only elevates treatment personalization but also provides critical data to inform real-world evidence generation. In addition, regulatory authorities have shown increasing receptivity to adaptive licensing pathways, facilitating accelerated approvals for therapies demonstrating substantial benefits in high-risk obesity populations. Collectively, these developments are redefining the contours of patient care and investment priorities across the industry.

Assessing the Far-Reaching Implications of Upcoming United States Tariff Policies on Oral Anorexiant Drug Supply Chains and Pricing Models

The impending implementation of the United States’ 2025 tariff schedule poses significant ramifications for the oral anorexiant supply chain and cost architecture. With proposals targeting key raw material imports and finished pharmaceutical products, manufacturers are proactively assessing the vulnerability of their procurement strategies. As a result, there is a pronounced shift toward regionalized sourcing and expanded onshore production to mitigate exposure to tariff-induced cost fluctuations.


In addition, payers and pharmacy benefit managers are expected to scrutinize pricing adjustments more rigorously, seeking to preserve formulary access amidst tightening reimbursement constraints. The combined effect of increased input costs and elevated commercial scrutiny has prompted leading organizations to explore vertically integrated manufacturing models and strategic collaborations with contract development and manufacturing partners. These measures aim to safeguard supply continuity while preserving margin integrity in a dynamic trade environment.

Illuminating Critical Patient Product and Distribution Segmentation Dimensions Shaping the Oral Anorexiant Drug Market Structure and Momentum

A nuanced understanding of market segmentation is foundational to optimizing product positioning and commercialization strategies within the oral anorexiant domain. Based on product classification, the landscape is comprised of both branded and generic formulations, each presenting distinct regulatory pathways, pricing dynamics, and stakeholder expectations. In terms of mechanisms of action, the category spans GLP-1 agonists-differentiated further into long-acting and short-acting agents-alongside lipase inhibitors and serotonin receptor agonists, reflecting diverse approaches to appetite suppression and metabolic modulation.


Distribution channels serve as critical touchpoints for patient access, encompassing hospital pharmacies, online pharmacies, and retail pharmacies, each with unique operational and reimbursement considerations. Dosage form preferences, whether capsules, oral solutions, or tablets, influence patient adherence patterns and administration convenience. From an end-user perspective, treatments are dispensed across home care settings, hospital environments, and specialty clinics, necessitating tailored support models. Finally, delineation by indication, covering obesity and overweight with comorbidities, in addition to patient age groups segmented into adult and pediatric cohorts, enables targeted clinical trial design and marketing initiatives that resonate with the specific needs of each demographic segment.

Analyzing the Distinct Regional Drivers and Regulatory Influences Across the Americas Europe Middle East & Africa and Asia-Pacific Anorexiant Therapy Markets

Regional dynamics exert a powerful influence on the adoption and commercialization of oral anorexiant therapies. Within the Americas, robust public health initiatives aimed at curbing obesity, paired with a favorable reimbursement landscape, have accelerated uptake of novel treatments. Cross-border trade agreements and established logistics networks further support efficient distribution, enabling manufacturers to rapidly scale access across diverse healthcare settings.


In Europe, Middle East & Africa, regulatory heterogeneity presents both challenges and opportunities. While centralized approval processes can streamline market entry within the European Union, evolving regulatory frameworks in MENA markets demand localized evidence generation and stakeholder engagement. The interplay of public sector procurement models and emerging private payers fuels competitive tendering processes and value-based contracting discussions.


Across Asia-Pacific, rising disposable incomes, increasing urbanization, and expanding healthcare infrastructure are driving demand for effective weight-management solutions. Government-led initiatives to address noncommunicable diseases, together with incentives for local manufacturing, are reshaping the competitive calculus. As a result, stakeholders in the region are prioritizing partnerships with local distributors and strategic investments in technology platforms to support scalable uptake.

Profiling the Strategic Imperatives and Competitive Differentiators Guiding Leading Oral Anorexiant Drug Manufacturers and Innovators

Leading pharmaceutical companies are deploying multifaceted strategies to solidify their positions within the oral anorexiant arena. Strategic mergers and acquisitions have enabled rapid expansion of product portfolios, while targeted licensing agreements are accelerating pipeline diversification in key therapeutic sub-segments. Moreover, several organizations are forging alliances with technology firms to integrate digital adherence tools, thereby enhancing patient support services and generating longitudinal outcome data.


R&D investments are increasingly concentrated on next-generation GLP-1 agents, including dual receptor modulators and combination formulations, which have demonstrated promising efficacy signals in clinical trials. Additionally, manufacturers are optimizing their manufacturing footprints by leveraging regional contract development and manufacturing organizations, reducing capital expenditure and enhancing supply chain agility. These initiatives underscore a broader trend toward value-driven innovation and evidence-based differentiation, as companies vie for market leadership in a rapidly evolving therapeutic class.

Crafting High-Impact Strategic Recommendations to Navigate Evolving Regulations Optimize Market Access and Drive Oral Anorexiant Therapy Adoption

Industry leaders must adopt a forward-leaning approach to capitalize on emerging opportunities within the oral anorexiant segment. First, fortifying supply chain resilience through diversified sourcing and domestic production capabilities will be paramount in light of shifting trade policies and tariff structures. This requires proactive engagement with contract manufacturers and logistics partners to ensure uninterrupted access to critical raw materials and finished dosage forms.


In parallel, stakeholders should prioritize early collaboration with payers and healthcare systems to establish value propositions that underscore real-world efficacy and safety. Generating robust health economic data through pragmatic clinical studies will facilitate formulary inclusion and support value-based contracting. Furthermore, investment in digital health solutions-such as remote monitoring applications and adherence platforms-will enhance patient engagement, improve outcomes, and differentiate offerings in a crowded marketplace.


Lastly, cultivating partnerships with specialty clinics and leveraging telemedicine channels can expand reach into underserved patient populations. By integrating targeted patient support programs, companies can strengthen brand loyalty and drive sustained adherence, thereby reinforcing long-term revenue streams.

Detailing the Comprehensive Research Framework Data Collection Techniques and Analytical Approaches Underpinning the Oral Anorexiant Market Study

This analysis is grounded in a rigorous research framework that combines primary and secondary methodologies to ensure depth, accuracy, and relevance. Primary research encompassed in-depth interviews with key opinion leaders, including endocrinologists, bariatric specialists, payers, and procurement executives, providing direct insights into clinical practice patterns, reimbursement dynamics, and emerging therapeutic preferences.


Secondary research involved comprehensive reviews of regulatory filings, patent databases, company disclosures, and peer-reviewed literature to track product approvals, pipeline developments, and competitive maneuvers. Data triangulation methods were employed to reconcile discrepancies across sources, enhancing the validity of the findings. Statistical analyses and thematic coding techniques were applied to qualitative inputs, facilitating robust segmentation and trend identification.


Throughout the study, iterative validation workshops were conducted with industry experts to test hypotheses, refine assumptions, and calibrate projections. This comprehensive methodology ensures that the insights presented are not only reflective of current market realities but also poised to inform strategic decision-making within a rapidly evolving oral anorexiant landscape.

Synthesizing Key Insights and Forward-Looking Perspectives to Inform Strategic Decision-Making in the Oral Anorexiant Therapeutics Domain

In synthesizing the critical findings, it is evident that the oral anorexiant market is on the cusp of significant expansion driven by innovative mechanisms, regulatory flexibility, and heightened clinical focus on obesity management. The interplay of product differentiation, strategic pricing, and patient-centric service models will shape competitive dynamics over the next horizon.


Key segmentation insights underscore the importance of tailoring commercialization efforts across branded and generic offerings, diverse mechanisms of action, and multi-channel distribution networks. Meanwhile, regional analyses reveal distinct regulatory and reimbursement landscapes that require localized strategies to optimize market penetration. Competitive profiling highlights the ongoing race to develop next-generation agents that deliver superior efficacy, safety, and convenience.


Ultimately, stakeholders armed with these insights will be better equipped to navigate trade policy shifts, align with payer expectations, and deliver compelling value propositions to healthcare providers and patients alike. This report serves as a strategic compass for organizations seeking to strengthen their market position and drive sustainable growth in the oral anorexiant therapeutic space.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Product
    • Branded
    • Generic
  • Mechanism Of Action
    • Glp-1 Agonists
      • Long-Acting Agents
      • Short-Acting Agents
    • Lipase Inhibitors
    • Serotonin Agonists
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Dosage Form
    • Capsule
    • Oral Solution
    • Tablet
  • End User
    • Home Care
    • Hospital
    • Specialty Clinics
  • Indication
    • Obesity
    • Overweight With Comorbidities
  • Patient Age Group
    • Adult
    • Pediatric

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan

This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Vivus, Inc.
  • Orexigen Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Ltd
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surging adoption of oral GLP-1 receptor agonists driven by improved efficacy and safety profiles
5.2. Expansion of telehealth platforms to support remote monitoring of patients on oral anorexiant regimens
5.3. Growing pipeline of dual agonist molecules targeting GLP-1 and GIP receptors for weight management
5.4. Increasing collaborations between pharmaceutical companies and digital health startups for adherence tracking
5.5. Heightened focus on affordability initiatives to broaden access to oral anorexiant medications in emerging markets
5.6. Integration of pharmacogenomic testing to optimize dosing strategies for oral anorexiant drugs
5.7. Regulatory momentum favoring accelerated approval pathways for novel oral appetite suppressant agents
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oral Anorexiant Drug Market, by Product
8.1. Introduction
8.2. Branded
8.3. Generic
9. Oral Anorexiant Drug Market, by Mechanism Of Action
9.1. Introduction
9.2. Glp-1 Agonists
9.2.1. Long-Acting Agents
9.2.2. Short-Acting Agents
9.3. Lipase Inhibitors
9.4. Serotonin Agonists
10. Oral Anorexiant Drug Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Oral Anorexiant Drug Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Oral Solution
11.4. Tablet
12. Oral Anorexiant Drug Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospital
12.4. Specialty Clinics
13. Oral Anorexiant Drug Market, by Indication
13.1. Introduction
13.2. Obesity
13.3. Overweight With Comorbidities
14. Oral Anorexiant Drug Market, by Patient Age Group
14.1. Introduction
14.2. Adult
14.3. Pediatric
15. Americas Oral Anorexiant Drug Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Oral Anorexiant Drug Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Oral Anorexiant Drug Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novo Nordisk A/S
18.3.2. F. Hoffmann-La Roche Ltd
18.3.3. GlaxoSmithKline plc
18.3.4. Vivus, Inc.
18.3.5. Orexigen Therapeutics, Inc.
18.3.6. Teva Pharmaceutical Industries Ltd
18.3.7. Sandoz International GmbH
18.3.8. Dr. Reddy’s Laboratories Ltd
18.3.9. Lupin Limited
18.3.10. Sun Pharmaceutical Industries Ltd
19. Research AI20. Research Statistics21. Research Contacts22. Research Articles23. Appendix
List of Figures
FIGURE 1. ORAL ANOREXIANT DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ORAL ANOREXIANT DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ORAL ANOREXIANT DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ORAL ANOREXIANT DRUG MARKET: RESEARCHAI
FIGURE 30. ORAL ANOREXIANT DRUG MARKET: RESEARCHSTATISTICS
FIGURE 31. ORAL ANOREXIANT DRUG MARKET: RESEARCHCONTACTS
FIGURE 32. ORAL ANOREXIANT DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL ANOREXIANT DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY LONG-ACTING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY LONG-ACTING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY SHORT-ACTING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY SHORT-ACTING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY SEROTONIN AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY SEROTONIN AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY OBESITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY OBESITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY OVERWEIGHT WITH COMORBIDITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORAL ANOREXIANT DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ORAL ANOREXIANT DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 102. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 103. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 104. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 105. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 106. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 107. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 110. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 111. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 116. CANADA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 117. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 118. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 119. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 199. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 200. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 201. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. GERMANY ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 216. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 217. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. FRANCE ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 248. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 249. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 250. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 251. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 252. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 253. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 256. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 257. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 262. ITALY ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 263. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 264. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 265. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 266. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 278. SPAIN ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA ORAL ANOREXIANT DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 327. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 328. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 329. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 330. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 331. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 332. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 333. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 334. DENMARK ORAL ANOREXIANT DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oral Anorexiant Drug Market report include:
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Vivus, Inc.
  • Orexigen Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Ltd
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd

Related Topics

Related Reports

Catecholamines Anorexiant Drug Market by Product Type (Benzphetamine, Diethylpropion, Ephedrine), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Route Of Administration, Dosage Form, End User - Global Forecast 2025-2030 - Product Image

Catecholamines Anorexiant Drug Market by Product Type (Benzphetamine, Diethylpropion, Ephedrine), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Route Of Administration, Dosage Form, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Anorexiants - Global Strategic Business Report - Product Image

Anorexiants - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Anorexiants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Anorexiants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Anorexiants Market 2024-2028 - Product Image

Anorexiants Market 2024-2028

  • Report
  • 138 Pages
  • Global
From
GLP-1 Targeted Peptide Weight Loss Drugs Market by Product Type (Injectable, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Dosage Strength, End User, Therapy Line, Patient Age Group, Patient Gender, Bmi Category - Global Forecast 2025-2030 - Product Image

GLP-1 Targeted Peptide Weight Loss Drugs Market by Product Type (Injectable, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Dosage Strength, End User, Therapy Line, Patient Age Group, Patient Gender, Bmi Category - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.